These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 16303295

  • 1. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B, Rouzier R, Kruse M, Dobson C, Ayre G, Horowitz A, Fitoussi S.
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [Abstract] [Full Text] [Related]

  • 2. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
    Kruse M, Rosenkranz B, Dobson C, Ayre G, Horowitz A.
    Pulm Pharmacol Ther; 2005 Apr; 18(3):229-34. PubMed ID: 15707858
    [Abstract] [Full Text] [Related]

  • 3. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
    Goldkorn A, Diotto P, Burgess C, Weatherall M, Holt S, Beasley R, Siebers R.
    Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W, Levine B, Andriano K, Lavecchia C, Yegen U.
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [Abstract] [Full Text] [Related]

  • 5. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M, D'Amato M, Califano C, Di Perna F, Calderaro E, Matera MG, D'Amato G.
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [Abstract] [Full Text] [Related]

  • 6. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 7. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A, Szalai Z, Pullerits T, Radeczky E.
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [Abstract] [Full Text] [Related]

  • 8. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
    Dahl R, Creemers JP, Van Noord J, Sips A, Della Cioppa G, Thomson M, Andriano K, Kottakis J, Fashola T.
    Respiration; 2004 Sep; 71(2):126-33. PubMed ID: 15031566
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma.
    Najafizadeh K, Sohrab Pour H, Ghadyanee M, Shiehmorteza M, Jamali M, Majdzadeh S.
    Emerg Med J; 2007 May; 24(5):317-21. PubMed ID: 17452695
    [Abstract] [Full Text] [Related]

  • 15. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
    Dubakiene R, Nargela R, Sakalauskas R, Vahteristo M, Silvasti M, Lähelmä S.
    Respiration; 2006 May; 73(4):441-8. PubMed ID: 16432294
    [Abstract] [Full Text] [Related]

  • 16. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhász G.
    Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
    Bouros D, Kottakis J, Le Gros V, Overend T, Della Cioppa G, Siafakas N.
    Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
    [Abstract] [Full Text] [Related]

  • 19. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
    Kharidia J, Fogarty CM, Laforce CF, Maier G, Hsu R, Dunnington KM, Curry L, Baumgartner RA, Hanrahan JP.
    Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
    [Abstract] [Full Text] [Related]

  • 20. Formoterol Turbuhaler as reliever medication in patients with acute asthma.
    Rubinfeld AR, Scicchitano R, Hunt A, Thompson PJ, Van Nooten A, Selroos O.
    Eur Respir J; 2006 Apr; 27(4):735-41. PubMed ID: 16455838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.